ImmunoPrecise Antibodies Ltd News - IPA

ImmunoPrecise Antibodies to Participate in January Conferences

IMMUNOPRECISE ANTIBODIES LTD. (“IPA”) (Nasdaq: IPA) (TSXV: IPA) a leader in full-service, therapeutic antibody discovery, today announced that...

ImmunoPrecise s'associe au lancement du programme de thérapie nanomédicale contre le SARS-CoV-2

Une approche innovante et inédite de traitement et de protection contre le SRAS-CoV-2 sous forme d'inhalation utilisant des nanoparticules...

ImmunoPrecise Partners on Launch of SARS-CoV-2 Nanomedicine Therapy Program

Innovative, novel approach to treat and protect against SARS-CoV-2 using thermoresponsive virus-targeting nanoparticles as an inhalation medicine...

ImmunoPrecise Antibodies to Begin Trading on Nasdaq Stock Exchange

ImmunoPrecise Antibodies to Begin Trading on Nasdaq Stock Exchange Canada NewsWire VICTORIA, BC, Dec. 23, 2020...

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter of 2021 Fiscal Year

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter of 2021 Fiscal...

ImmunoPrecise and LiteVax Advance SARS-CoV-2 Vaccine Candidate

ImmunoPrecise and LiteVax Advance SARS-CoV-2 Vaccine Candidate Canada NewsWire VICTORIA, BC, Dec. 14, 2020...

ImmunoPrecise Collaboration Enables Preclinical Manufacturing of Lead Antibodies Targeting SARS-CoV-2

ImmunoPrecise Collaboration Enables Preclinical Manufacturing of Lead Antibodies Targeting SARS-CoV-2 Canada...

ImmunoPrecise Antibodies Ranked Number 240 Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™

ImmunoPrecise Antibodies Ranked Number 240 Fastest-Growing Company in North America on Deloitte's 2020...

IPA Selects Polytope™ Formulations for Pre-Clinical Studies

IPA Selects Polytope™ Formulations for Pre-Clinical Studies Canada NewsWire VICTORIA, BC, Nov. 23, 2020...

ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease

ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease Canada...

ImmunoPrecise Antibodies Confirms Effective Date of Share Consolidation

ImmunoPrecise Antibodies Confirms Effective Date of Share Consolidation Canada NewsWire VICTORIA, BC, Nov. 17...

ImmunoPrecise Antibodies Files Preliminary Base Shelf Prospectus and Registration Statement

ImmunoPrecise Antibodies Files Preliminary Base Shelf Prospectus and Registration Statement Canada...

ImmunoPrecise Antibodies to Complete Share Consolidation in Preparation for Potential Nasdaq Listing

ImmunoPrecise Antibodies to Complete Share Consolidation in Preparation for Potential Nasdaq Listing Canada...

ImmunoPrecise Antibodies and Mila Announce Strategic AI Partnership

ImmunoPrecise Antibodies and Mila Announce Strategic AI Partnership Canada NewsWire VICTORIA, BC, Nov. 3, 2020...

ImmunoPrecise and Twist Bioscience Announce Collaboration for the Creation of Novel, Therapeutic Products

ImmunoPrecise and Twist Bioscience Announce Collaboration for the Creation of Novel, Therapeutic...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

ImmunoPrecise Antibodies Ltd (IPA)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

IPA News

ImmunoPrecise Antibodies to Participate in January Conferences

ImmunoPrecise s'associe au lancement du programme de thérapie nanomédicale contre le SARS-CoV-2

ImmunoPrecise Partners on Launch of SARS-CoV-2 Nanomedicine Therapy Program

ImmunoPrecise Antibodies to Begin Trading on Nasdaq Stock Exchange

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter of 2021 Fiscal Year

ImmunoPrecise and LiteVax Advance SARS-CoV-2 Vaccine Candidate

ImmunoPrecise Collaboration Enables Preclinical Manufacturing of Lead Antibodies Targeting SARS-CoV-2

ImmunoPrecise Antibodies Ranked Number 240 Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™

IPA Selects Polytope™ Formulations for Pre-Clinical Studies

ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease

ImmunoPrecise Antibodies Confirms Effective Date of Share Consolidation

ImmunoPrecise Antibodies Files Preliminary Base Shelf Prospectus and Registration Statement

ImmunoPrecise Antibodies to Complete Share Consolidation in Preparation for Potential Nasdaq Listing

ImmunoPrecise Antibodies and Mila Announce Strategic AI Partnership

ImmunoPrecise and Twist Bioscience Announce Collaboration for the Creation of Novel, Therapeutic Products

IPA Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

ImmunoPrecise Antibodies Ltd (IPA) News

ImmunoPrecise Antibodies Ltd (IPA)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

IPA News

ImmunoPrecise Antibodies to Participate in January Conferences

ImmunoPrecise s'associe au lancement du programme de thérapie nanomédicale contre le SARS-CoV-2

ImmunoPrecise Partners on Launch of SARS-CoV-2 Nanomedicine Therapy Program

ImmunoPrecise Antibodies to Begin Trading on Nasdaq Stock Exchange

ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter of 2021 Fiscal Year

ImmunoPrecise and LiteVax Advance SARS-CoV-2 Vaccine Candidate

ImmunoPrecise Collaboration Enables Preclinical Manufacturing of Lead Antibodies Targeting SARS-CoV-2

ImmunoPrecise Antibodies Ranked Number 240 Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™

IPA Selects Polytope™ Formulations for Pre-Clinical Studies

ImmunoPrecise and Genmab Enter into a Technology Partnership Targeting Infectious Disease

ImmunoPrecise Antibodies Confirms Effective Date of Share Consolidation

ImmunoPrecise Antibodies Files Preliminary Base Shelf Prospectus and Registration Statement

ImmunoPrecise Antibodies to Complete Share Consolidation in Preparation for Potential Nasdaq Listing

ImmunoPrecise Antibodies and Mila Announce Strategic AI Partnership

ImmunoPrecise and Twist Bioscience Announce Collaboration for the Creation of Novel, Therapeutic Products

IPA Discussion

Your Recent History